# Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer

> **NCT06853496** · PHASE1 · RECRUITING · sponsor: **Eiji Shinozaki** · enrollment: 48 (estimated)

## Conditions studied

- Unresectable Colorectal Neoplasm Metastasis

## Interventions

- **DRUG:** RK-582

## Key facts

- **NCT ID:** NCT06853496
- **Lead sponsor:** Eiji Shinozaki
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-13
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06853496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06853496, "Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06853496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*